Antibiotics 2022, 11(3), 329; https://doi.org/10.3390/antibiotics11030329.
The authors found that the most-represented antibiotics on the Rwandan market were amoxicillin, co-trimoxazole and cloxacillin. No counterfeit antibiotics were found in this study. However, substandard batches with moderate ...deviations were found, suggesting that regular quality control of antibiotics is needed in Rwanda.
more
ПАКЕТ МЕР ПО РЕАЛИЗАЦИИ ПОЛИТИКИ В ОТНОШЕНИИ ВНЕДРЕНИЯ НОВЫХ ПРОТИВОТУБЕРКУЛЕЗНЫХ ПРЕПАРАТОВ
For the Assesor's Guide Vol 1 and 2 see: nrhm.gov.in/images/pdf/programmes/maternal-health/guidelines/Operational_Guidelines_for_Quality_Assurance_in_Public_Health_Facilities_and_checklists-3_books.zip
Training for staff working at DR-TB management centres.
Training modules
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):858–864.Namibia ranks among the 30 high TB burden countries worldwide. Here, we report results of the second nationwide anti-TB drug resistance survey. To assess the prevalence and trends of multidrug-resistant TB (MDR-TB) in Namibia.
From 2014 to 2015, pat...ients with presumptive TB in all regions of Namibia had sputum subjected to mycobacterial culture and phenotypic drug susceptibility testing (DST) for rifampicin, isoniazid, ethambutol and streptomycin if positive on smear microscopy and/or Xpert MTB/RIF.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more
10 years after the UN general assembly special session on drugs
The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i...) improve the detection of resistance to ensure a timely response; ii) delay the emergence of resistance to artemisinin and artemisinin-based combination therapy (ACT) partner drugs; and iii) limit the selection and spread of resistant parasites where resistance has been confirmed.
WHO Team
Global Malaria Programme
Editors
World Health Organization
Number of pages
87
Reference numbers
ISBN: 978 92 4 006026 5
Copyright
more
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
National Action Plan: Programmatic Management of Drug Resistance Tuberculosis, Tuberculosis Control Indonesia
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
Lancet Infect Dis 2020 Published Online May 5, 2020 https://doi.org/10.1016/ S1473-3099(20)30254-1